Address: 2 et 4 rue Lionel Terray
BP 308
92 506 Rueil-Malmaison Cedex,France
Tel: 01 55 47 67 66
Novartis International AG is a world pharmaceutical leader based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.173 billon in 2008.
Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis owns Sandoz, a large manufacturer of generic drugs.
The French market represents the third biggest source of revenues to the company worldwide.
The company has an extensive array of products that go from pharmaceuticals to vaccines and diagnosis, generics, OTCs, animal health and others.
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now…
The recently appointed general manager of Galderma France, reveals the company’s ambitious objective for the next ten years: to increase sales from two to ten billion Euros (2.18 billion USD to…
Eric Goupil reveals how the global CMO market has expanded considerably over recent years, with a move towards a more strategic mind-set in the pharmaceutical industry. Unither´s business model is…
The presence in France of Swiss medical compression garment manufacturer Sigvaris dates back more than 100 years. The current president, Alain Bertheas, describes the company’s history and explains its garments.…
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through…
Arnaud Pradel, Product Development Director and Co-Segment Leader of HORIBA Medical reveals how HORIBA has over 30 years of experience when it comes to launching products in the vitro diagnostic…
The president of the family-run Laboratoires Panpharma, a specialist in injectable drugs for the hospital sector, reveals how they have affiliates in both France and Germany, are in the process of…
Philippe Luscan reveals how Sanofi contributes almost USD 6.35 billion net to the French economy; how their five new global business units will drive future growth, and why they are…
Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system…
Novasep is the largest contract manufacturer for the pharmaceuticals and fine chemicals industries in France. Michel Spagnol, the company’s chairman and CEO, highlights recent reorganization and “back to basics” strategy…
Lyon provides companies with a flamboyant and collaborative environment to develop. Bruno Masurel, Head of the International Division of the local Chamber of Commerce talks about the advantages the region…
Erin Gainer, the CEO of HRA Pharma, reveals how the company has significantly grown its business in the fields of women’s health and endocrinology over the past decade to become…
See our Cookie Privacy Policy Here
